Spots Global Cancer Trial Database for Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

Official Title: Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

Study ID: NCT04942730

Conditions

Leukemia, Acute Lymphoblastic

Myeloid Leukemia, Acute

Biphenotypic Acute Leukemia

Lymphoblastic Lymphoma

Myelodysplastic Syndromes

Myeloproliferative Neoplasm

Interventions

Fludarabine

Bendamustine Hydrochloride

Busulfan

Cyclophosphamide

Mycophenolate Mofetil

Tacrolimus 5Mg Cap

Study Description

Brief Summary: Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure. Different technologies of with replete or depleted graft are associated with 10-20% of graft failures. Fludarabine and busulfan conditioning is the most commonly used approach for a variety of disease. Furthermore combination of fludarabine and bendamustine was sufficient to facilitate engraftment in patients with chronic lymphocytic leukemia and lymphomas. The aim of the study is to evaluate whether addition of bendamustine to fladarabine and busulfan conditioning reduces the risk of primary graft failure after haploidentical allograft.

Detailed Description: